<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The receptor for human interleukin-9 (hIL-9) might be a target for selective immunotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>It is expressed on a variety of malignant cells, including Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore constructed a new chimeric toxin by fusing hIL-9-cDNA to modified Pseudomonas aeruginosa exotoxin A (<z:chebi fb="209" ids="16000,53460">ETA</z:chebi>') </plain></SENT>
<SENT sid="3" pm="."><plain>The binding properties of the new recombinant protein, rhIL-9-<z:chebi fb="209" ids="16000,53460">ETA</z:chebi>', were assessed on different cell lines expressing the hIL-9 receptor </plain></SENT>
<SENT sid="4" pm="."><plain>The antitumor potency of rhIL-9-<z:chebi fb="209" ids="16000,53460">ETA</z:chebi>' was evaluated against the Hodgkin-derived cell lines L540Cy, KM-H2 and L1236, the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell line Daudi, the <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> cell line K562, and the <z:mpath ids='MPATH_350'>mastocytoma</z:mpath> cell line P815-hIL9R, transfected with hIL-9 receptor cDNA </plain></SENT>
<SENT sid="5" pm="."><plain>Recombinant hIL-9-<z:chebi fb="209" ids="16000,53460">ETA</z:chebi>' exhibited potent specific cytotoxic effects against P815-hIL9R, K562 and L1236 cells, inhibiting protein synthesis by 50% (IC50) at concentrations of 0.05, 0.58 and 3 micrograms/ml respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The cytotoxic effect was abrogated after addition of polyclonal antibodies against the human IL-9 </plain></SENT>
<SENT sid="7" pm="."><plain>rhIL-9-<z:chebi fb="209" ids="16000,53460">ETA</z:chebi>' might be of potential use against hIL-9R-expressing <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>